PVI
ZYNE

Pura Vida Investments’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Pura Vida Investments’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-30,000
Closed -$603K – 97
2017
Q1 		$603K Buy
+30,000
New +$596K 0.18% 67

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Pura Vida Investments's ZYNE Position: Q2 2017 in Review

Pura Vida Investments sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2017, closing a stake of 30,000 shares — an estimated $603K sold.

Pura Vida Investments first reported a position in ZYNE in Q1 2017 and held it in 1 quarter. The position peaked at $603K in Q1 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q2 2017.

  • Pura Vida Investments reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Pura Vida Investments sold 30,000 Zynerba Pharmaceuticals, Inc shares in Q2 2017, an estimated $603K.
  • Pura Vida Investments first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 1 quarter.
  • Pura Vida Investments's Zynerba Pharmaceuticals, Inc position peaked at $603K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2017.

Based on Pura Vida Investments's 13F filing for Q2 2017, filed 14 Aug 2017.